Skip to content

Study · Non-randomized trial · 1990

5 results

Efficacy and safety of nafarelin in the treatment of endometriosis.

Henzl MR, Kwei L

American journal of obstetrics and gynecology1 Feb 1990Cited by 29 (Europe PMC)

PMID2137971 (opens in a new tab)DOI10.1016/0002-9378(90)90432-7 (opens in a new tab)PepBankPUB-02137971
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with endometriosis, assessments of symptoms, laparoscopic scores, and pregnancy rates indicated similar efficacy with nafarelin and danazol.

    In plain wordsIn patients with endometriosis, symptom, laparoscopy, and pregnancy assessments indicated similar efficacy with nafarelin and danazol.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedOverall efficacy assessed by symptoms, laparoscopic scores, and pregnancy rates
    Study

    n: not reported in source

    Comparator
    Oral danazol 600 and 800 mg
    Outcome group
    Organ injury · Reproductive and sexual health
    Studied dose
    400 and 800 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Assessments of severity of symptoms, laparoscopic scores before and after therapy, and pregnancy rates showed that nafarelin, 400 and 800 micrograms administered intranasally, was as efficacious as oral danazol, 600 and 800 mg.
    1 context sentence
    Summary · context
    The efficacy and safety of the gonadotropin-releasing hormone agonist nafarelin for treatment of endometriosis were compared with those of danazol in two large-scale, double-blind trials.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with endometriosis, nafarelin adverse effects mainly included hot flashes associated with hypoestrogenemia.

    In plain wordsIn patients with endometriosis, hot flashes were the main reported nafarelin side effect.

    Peptide
    Nafarelin
    Outcome
    Not applicableHot flashes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    400 and 800 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    The adverse effects seen with nafarelin, mainly hot flashes, were related to its mode of action, namely hypoestrogenemia induced by reversible inhibition of ovarian hormone production.
    1 context sentence
    Summary · context
    The efficacy and safety of the gonadotropin-releasing hormone agonist nafarelin for treatment of endometriosis were compared with those of danazol in two large-scale, double-blind trials.
  3. 03HumanNon-randomized trialSafety outcome

    In patients treated with nafarelin for endometriosis, hypoestrogenemia was associated with decreased lumbar vertebral bone density.

    In plain wordsIn patients treated with nafarelin for endometriosis, low estrogen was linked to reduced lower-spine bone density.

    Peptide
    Nafarelin
    Outcome
    DecreaseLumbar vertebral bone density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 and 800 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Hypoestrogenemia was associated with a decrease of bone density in the lumbar vertebrae, but these changes were partially or completely reversible after treatment was discontinued.
    2 context sentences
    Summary · context
    The adverse effects seen with nafarelin, mainly hot flashes, were related to its mode of action, namely hypoestrogenemia induced by reversible inhibition of ovarian hormone production.
    Summary · context
    The efficacy and safety of the gonadotropin-releasing hormone agonist nafarelin for treatment of endometriosis were compared with those of danazol in two large-scale, double-blind trials.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with endometriosis, lumbar bone density changes were partially or completely reversible after nafarelin discontinuation.

    In plain wordsIn patients with endometriosis, lower-spine bone density changes partly or fully reversed after nafarelin stopped.

    Peptide
    Nafarelin
    Outcome
    Not applicableLumbar bone density recovery
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 and 800 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Hypoestrogenemia was associated with a decrease of bone density in the lumbar vertebrae, but these changes were partially or completely reversible after treatment was discontinued.
    1 context sentence
    Summary · context
    The efficacy and safety of the gonadotropin-releasing hormone agonist nafarelin for treatment of endometriosis were compared with those of danazol in two large-scale, double-blind trials.
  5. 05HumanNon-randomized trialSafety outcome

    In patients treated with nafarelin for endometriosis, distal radius bone mass did not change significantly.

    In plain wordsIn patients treated with nafarelin for endometriosis, forearm bone mass did not change significantly.

    Peptide
    Nafarelin
    Outcome
    No significant changeDistal radius bone mass
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 and 800 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    No significant changes in bone mass occurred in the distal radius.
    1 context sentence
    Summary · context
    The efficacy and safety of the gonadotropin-releasing hormone agonist nafarelin for treatment of endometriosis were compared with those of danazol in two large-scale, double-blind trials.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.